Table 2.1.
Number of Patients with ALL Adverse Events (AEs) according to cabozantinib dose level
| cabozantinib dose level | TOTAL | |||||||
|---|---|---|---|---|---|---|---|---|
| cabozantinib 20mg, abiraterone 1000mg |
cabozantinib 40mg, abiraterone 1000mg |
cabozantinib 60mg, abiraterone 1000mg |
||||||
| N | % | N | % | N | % | N | % | |
| Maximum Grade* | 2 | 16.7 | 1 | 8.3 | - | - | 3 | 11.1 |
| 1 | ||||||||
| 2 | 5 | 41.7 | 1 | 8.3 | 1 | 33.3 | 7 | 25.9 |
| 3 | 5 | 41.7 | 8 | 66.7 | - | - | 13 | 48.1 |
| 4 | - | - | 2 | 16.7 | 2 | 66.7 | 4 | 14.8 |
| Total | 12 | 100.0 | 12 | 100.0 | 3 | 100.0 | 27 | 100.0 |
*
maximum grade consolidates reports of all AEs of same type for a patient.